Leqembi (Lecanemab) Treatment
Leqembi (Lecanemab) infusions are a promising new treatment option to slow down the cognitive and functional decline associated with Alzheimer’s disease. Leqembi treatment is a targeted approach to reduce the accumulation of amyloid beta protein, which research has shown to play a critical role in the onset and progression of Alzheimer’s disease. By reducing the accumulation of amyloid plaques in the brain, this medication and others like it delay cognitive decline in individuals with Alzheimer’s disease. This translates to better quality of life for both patients, families, and caregivers.
What is Leqembi and How Does it Work?
Leqembi is an antibody therapy designed to target the amyloid beta protein, which contributes to the development and progression of Alzheimer’s disease. By binding to and clearing amyloid plaques from the brain, Leqembi slows down the progression of the disease.
How is Leqembi Administered?
The medication is administered through intravenous infusion (IV), at a dosage of 10 mg/kg every two weeks for a maximum duration of 18 months.
Who Qualifies for Leqembi Infusions?
Individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease are candidates for Leqembi infusions. Our neurology team will review your medical history, perform a thorough evaluation and confirm the presence of the amyloid protein to make sure you qualify for Leqembi.
How Do I Schedule a Consultation or Refer a Patient?
Patients who are interested in Leqembi must be evaluated by a memory disorder specialist to first determine if Leqembi is an appropriate treatment for their condition. Further, the risks, benefits, and side effects of the medication must be explained in detail so patients can make an informed decision about their care. Patients should visit their primary care doctors for a referral to The Neuron Clinic.